☆ 4.7 Letter

Very late relapses in glioblastoma long-term survivors

JOURNAL OF NEUROLOGY (2009)

期刊

JOURNAL OF NEUROLOGY

卷 256, 期 10, 页码 1756-1758

出版社

DR DIETRICH STEINKOPFF VERLAG

DOI: 10.1007/s00415-009-5167-6

关键词

-

类别

Clinical Neurology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Long-term survival of patients with histologically confirmed glioblastoma is a rare event with figures in the range of 2-3% for 5-year survival (Scott et al. in Ann Neurol 46:183-188, 1999; McLendon and Halperin in Cancer 98:1745-1748, 2003; Krex et al. in Brain 130:2596-2606, 2007). Prognosis and further clinical course of these patients beyond 5 years after diagnosis are in essence unknown with only anecdotal reports of patients surviving for 10 years or more (Salvati et al. J Neurooncol 36:61-64, 1998). We here report on the extended follow-up (mean, 139.4 months) of a cohort of glioblastoma long-term survivors. Very late relapses occurred in many patients even after more than 10 years of progression-free survival.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Predictive factors of long-term follow-up attendance in very long-term childhood cancer survivors

Agnes Dumas, Karen Milcent, Nicolas Bougas, Daniel Bejarano-Quisoboni, Chiraz El Fayech, Helene Charreire, Odile Oberlin, Catherine Patte, Julie Allard, Eric Thebault, Amel Boumaraf, Amel Belhout, Vu-Bezin Giao, Vincent Souchard, Angela Jackson, Rodrigue Allodji, Dominique Valteau-Couanet, Christelle Dufour, Gilles Vassal, Nadia Haddy, Florent De Vathaire, Brice Fresneau

Summary: The study found that patients who received combined chemotherapy and radiotherapy, had bone sarcoma, central nervous system primitive tumor, or underwent autologous hematopoietic cell transplant were more likely to attend long-term follow-up visits. Additionally, factors such as health status, medical expenses, social status, and distance from the follow-up center also influenced attendance.

CANCER (2023)

添加到收藏夹

Article Oncology

Late effects, long-term problems and unmet needs of cancer survivors

Martina E. Schmidt, Siri Goldschmidt, Silke Hermann, Karen Steindorf

Summary: Significant efforts have been made in cancer treatment, leading to improved survival rates. However, research and care for long-term problems and late effects in cancer survivors are inadequate. This study found that while cancer survivors' overall health-related quality of life and physical function were comparable or better than the general population, emotional and cognitive function were worse, particularly among women. Commonly reported problems with moderate burden included loss of physical performance, fatigue, sexual problems, sleep problems, and anxiety. Survivors often rated the support they received as poor, especially for non-threatening medical issues or issues without effective medication or treatment. Factors such as older age, female gender, history of chemotherapy, and overweight/obesity were associated with higher burdens. These findings highlight the need for increased awareness and targeted care for the long-term and late effects experienced by cancer survivors.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma

Paula Ofek, Eilam Yeini, Gali Arad, Artem Danilevsky, Sabina Pozzi, Christian Burgos Luna, Sahar Israeli Dangoor, Rachel Grossman, Zvi Ram, Noam Shomron, Henry Brem, Thomas M. Hyde, Tamar Geiger, Ronit Satchi-Fainaro

Summary: This study identified molecular markers associated with favorable prognosis in glioblastoma (GB) patients. Overexpression of DOHH, a gene involved in the biosynthesis of an amino acid essential for tumor growth, was found in short-term survivors (STS) and promoted tumor aggressiveness through the epithelial-mesenchymal transition (EMT) pathway.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Burden of late effects in a nationwide sample of long-term breast cancer survivors

Solveig K. Smedsland, Ragnhild S. Falk, Kristin V. Reinertsen, Cecilie E. Kiserud, Mette Brekke, Synne H. Bohn, Alv A. Dahl, Kathrine F. Vandraas

Summary: More than half of long-term breast cancer survivors suffer from medium or high burden of late effects. Younger age and systemic treatments are important risk factors for experiencing a higher symptom burden, and breast cancer survivors with these risk factors should be prioritized for closer and extended survivorship care.

CANCER (2023)

添加到收藏夹

Article Oncology

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma

Haihui Jiang, Kefu Yu, Yong Cui, Xiaohui Ren, Mingxiao Li, Guobin Zhang, Chuanwei Yang, Xuzhe Zhao, Qinghui Zhu, Song Lin

Summary: This study aimed to disclose the predictors and clinical implications associated with long-term survivors (LTS) in IDH wildtype and mutant GBM. LTS had younger age, higher KPS score, more cystic change, MGMT promoter methylation, IDH mutation, and were more likely to have undergone gross total resection compared to short-term survivors (STS). LTS with wildtype IDH conferred longer progression-free survival, but shorter post-progression survival, than those with mutant IDH. Additionally, the clinical benefit of re-operation and reirradiation in LTS with mutant IDH disappeared in LTS with wildtype IDH.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Oral and dental late effects in long-term survivors of childhood embryonal brain tumors

Kristine Eidal Tanem, Einar Stensvold, Petter Wilberg, Anne B. Skaare, Petter Brandal, Bente Brokstad Herlofson

Summary: This study investigated oral and dental late effects in survivors of childhood brain tumors, finding that reduced mouth opening and dental developmental disturbances were the most common issues, especially in survivors treated before the age of 5.

SUPPORTIVE CARE IN CANCER (2022)

添加到收藏夹

Article Oncology

Work Placement and Job Satisfaction in Long-Term Childhood Cancer Survivors: The Impact of Late Effects

Margherita Dionisi-Vici, Alessandro Godono, Anna Castiglione, Filippo Gatti, Nicoletta Fortunati, Marco Clari, Alessio Conti, Giulia Zucchetti, Eleonora Biasin, Antonella Varetto, Enrico Pira, Franca Fagioli, Enrico Brignardello, Francesco Felicetti

Summary: This study aims to describe the occupational status of long-term childhood cancer survivors (CCS) and evaluate the association between late effects and unemployment and job satisfaction. The results show that severe late effects have a negative impact on occupation and worsen the perception of satisfaction with the economic situation of unemployed CCS. Routine follow-up care for CCS should include monitoring their socioeconomic development and providing interventions to help them obtain suitable jobs.

CANCERS (2022)

添加到收藏夹

Article Oncology

A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors

Anna C. Nuijens, Arlene L. Oei, Anne Bouhuijs, Nicolaas A. P. Franken, Coen R. N. Rasch, Lukas J. A. Stalpers

Summary: Radiotherapy is commonly used to treat localized prostate cancer, but it can lead to late radiation toxicity. This study compared physician-reported and patient-reported outcomes in prostate cancer survivors and investigated the correlation with a biological predictor of late toxicity. The results showed that patients rated the severity of symptoms higher than the trial physician assistant did, indicating the importance of considering both perspectives for optimal care.

CANCERS (2022)

添加到收藏夹

Article Oncology

Kidney disease in very long-term survivors of Wilms tumor: A nationwide cohort study with sibling controls

Stine Hogsholt, Peter Haubjerg Asdahl, Catherine Rechnitzer, Jeanette Falck Winther, Henrik Birn, Henrik Hasle

Summary: This study aimed to investigate evidence of kidney disease in long-term survivors of Wilms tumor and found that these survivors have significantly decreased renal function, along with an increased risk for kidney disease and end-stage renal disease compared to sibling controls. However, most survivors still have kidney function within the normal range.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study

Melissa S. Y. Thong, Daniela Doege, Linda Weisser, Lena Koch-Gallenkamp, Heike Bertram, Andrea Eberle, Bernd Holleczek, Alice Nennecke, Annika Waldmann, Sylke Ruth Zeissig, Ron Pritzkuleit, Michael Schlander, Hermann Brenner, Volker Arndt

Summary: Limited research suggests that cancer survivors may have insurance problems. This study found that most survivors did not change their health insurance or try to buy life insurance after diagnosis. Issues with changing statutory health insurance were generally resolved with additional contribution, while the main problem when buying life insurance was rejection of requests.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Long-Term Cognitive Dysfunction in Cancer Survivors

Zuzana Orszaghova, Michal Mego, Michal Chovanec

Summary: Cancer-related cognitive impairment (CRCI) is a common side effect affecting the quality of life of cancer survivors, with unknown exact incidence and mechanisms. The symptoms are described as cognitive changes, but the association with objectively assessed cognitive changes is weak. Research has mainly focused on breast cancer patients, but CRCI has been reported in various types of cancer.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

添加到收藏夹

Article Oncology

Benign Tumors in Long-Term Survivors of Retinoblastoma

Milo van Hoefen Wijsard, Sara J. Schonfeld, Flora E. van Leeuwen, Annette C. Moll, Armida W. Fabius, David H. Abramson, Johanna M. Seddon, Jasmine H. Francis, Margaret A. Tucker, Ruth A. Kleinerman, Lindsay M. Morton

Summary: Hereditary retinoblastoma survivors have a substantially increased risk of developing subsequent malignant neoplasms (SMNs), and there is also a risk of developing benign tumors, which may impact long-term surveillance.

CANCERS (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Causes of Death in Long-Term Nasopharyngeal Carcinoma Survivors

Shi-Ping Yang, Ming-Yue Rao, Qing-Shuang Chen, Ping Zhou, Chen-Lu Lian, San-Gang Wu

Summary: This study assessed the causes of death and long-term survival after nasopharyngeal carcinoma (NPC) diagnosis. The results showed that primary NPC remains a significant cause of death even 15 years after diagnosis, while death due to cardiac disease and other causes increased over time. Age, race, and diagnosis time were identified as important factors affecting NPC-specific survival.

FRONTIERS IN PUBLIC HEALTH (2022)

添加到收藏夹

Article Oncology

Benefit finding in long-term prostate cancer survivors

Irene Lassmann, Andreas Dinkel, Birgitt Marten-Mittag, Matthias Jahnen, Helga Schulwitz, Jurgen E. Gschwend, Kathleen Herkommer

Summary: The study found that a high proportion of long-term prostate cancer survivors experience benefit finding, with younger age at diagnosis, lower educational level, and higher perceived severity of the disease experience being predictive factors. Objective disease severity or family history of PCa was not uniquely associated with benefit finding, suggesting that survivors may find benefits regardless of clinical disease severity.

SUPPORTIVE CARE IN CANCER (2021)

添加到收藏夹

Article Oncology

Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers

Annalisa Trama, Claudia Vener, Paolo Lasalvia, Alice Bernasconi, Ada Working Grp

Summary: The study found that adolescent and young adult survivors of hematological cancers are at increased risk for second malignant neoplasms, hospitalizations, and mortality, especially for leukemia survivors. The highest excess risks of hospitalizations were observed for infectious diseases, respiratory diseases, and diseases of blood and blood-forming organs. The morbidity patterns differ over time by type of morbidity.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Louis Burt Nabors, Manmeet S. Ahluwalia, Roger Stupp, Minesh P. Mehta, David A. Reardon, Stuart A. Grossman, Erik P. Sulman, John H. Sampson, Simon Khagi, Michael Weller, Timothy F. Cloughesy, Patrick Y. Wen, Mustafa Khasraw

Summary: This article reviews the limited therapeutic advances for glioblastoma and the failure of recent clinical trials, and emphasizes the need for improvement in clinical trial conduct. Challenges related to clinical trial eligibility criteria and trial design in glioblastoma are identified, and data-driven analysis of current glioblastoma clinical trials is provided.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma

Emilie Le Rhun, Felix Boakye Oppong, Maureen Vanlancker, Roger Stupp, Burt Nabors, Olivier Chinot, Wolfgang Wick, Matthias Preusser, Thierry Gorlia, Michael Weller

Summary: Myelosuppression during temozolomide chemoradiotherapy is associated with the survival of patients with newly diagnosed glioblastoma. Female patients experience more marrow toxicity than males. Lymphopenia is related to the overall survival of patients.

NEURO-ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller

Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group

Philipp Karschnia, Jacob S. Young, Antonio Dono, Levin Haeni, Tommaso Sciortino, Francesco Bruno, Stephanie T. Juenger, Nico Teske, Ramin A. Morshed, Alexander F. Haddad, Yalan Zhang, Sophia Stoecklein, Michael Weller, Michael A. Vogelbaum, Juergen Beck, Nitin Tandon, Shawn Hervey-Jumper, Annette M. Molinaro, Roberta Ruda, Lorenzo Bello, Oliver Schnell, Yoshua Esquenazi, Maximilian Ruge, Stefan J. Grau, Mitchel S. Berger, Susan M. Chang, Martin van den Bent, Joerg-Christian Tonn

Summary: This study investigated the prognostic value of the extent of resection in glioblastoma, finding that smaller volumes of residual contrast-enhancing tumor were associated with better outcomes. Additionally, removing non-contrast-enhancing tumor beyond the tumor borders resulted in improved survival. These findings have significant implications for stratification in clinical trials.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions

Marcel Buehler, Xiao Yi, Weigang Ge, Peter Blattmann, Elisabeth Rushing, Guido Reifenberger, Joerg Felsberg, Charles Yeh, Jacob E. Corn, Luca Regli, Junyi Zhang, Ann Cloos, Vidhya M. Ravi, Benedikt Wiestler, Dieter Henrik Heiland, Ruedi Aebersold, Michael Weller, Tiannan Guo, Tobias Weiss

Summary: In this study, the evolution of the proteomic landscape in glioblastoma from initial diagnosis to post-treatment recurrence was investigated. The authors identified BCAS1, INF2, and FBXO2 as consistently upregulated proteins at recurrence, and demonstrated that knockout of the FBXO2 gene conferred a survival benefit and reduced invasive growth. These findings suggest a potential role of FBXO2 in promoting tumor growth through glioma-microenvironment interactions.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg

Summary: The management of primary central nervous system lymphoma (PCNSL) is a controversial topic in neuro-oncology. The European Association of Neuro-Oncology (EANO) formed a multidisciplinary task force to update the evidence-based guidelines and include immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study

Philipp Vollmuth, Martha Foltyn, Raymond Y. Huang, Norbert Galldiks, Jens Petersen, Fabian Isensee, Martin J. van den Bent, Frederik Barkhof, Ji Eun Park, Yae Won Park, Sung Soo Ahn, Gianluca Brugnara, Hagen Meredig, Rajan Jain, Marion Smits, Whitney B. Pope, Klaus Maier-Hein, Michael Weller, Patrick Y. Wen, Wolfgang Wick, Martin Bendszus

Summary: This study aimed to assess the reproducibility and standardization of treatment response assessment using artificial intelligence (AI) decision support in MRI. The results showed that AI decision support can provide better evaluation of treatment response in patients with lower-grade gliomas compared to manual measurements.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

Sied Kebir, Vivien Ullrich, Pia Berger, Celia Dobersalske, Sarah Langer, Laurel Rauschenbach, Daniel Trageser, Andreas Till, Franziska K. Lorbeer, Anja Wieland, Timo Wilhelm-Buchstab, Ashar Ahmad, Holger Froehlich, Igor Cima, Shruthi Prasad, Johann Matschke, Verena Jendrossek, Marc Remke, Barbara M. Gruener, Alexander Roesch, Jens T. Siveke, Christel Herold-Mende, Tobias Blau, Kathy Keyvani, Frank K. H. van Landeghem, Torsten Pietsch, Jorg Felsberg, Guido Reifenberger, Michael Weller, Ulrich Sure, Oliver Bruestle, Matthias Simon, Martin Glas, Bjoern Scheffler

Summary: This study aimed to identify and target tumor cells that can survive, adapt, and expand under primary therapy in glioblastoma. The researchers found that ALDH1A1+/pAKT+ subclones accumulate and acquire drug resistance in response to temozolomide treatment. They propose a combination therapy of temozolomide and AKT inhibitors as a potential treatment strategy.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101

Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller

Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Review Oncology

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Jana Portnow, Ovidiu Andronesi, Jill S. Barnholtz-Sloan, Brigitta G. Baumert, Mitchell S. Berger, Wenya Linda Bi, Ranjit Bindra, Daniel P. Cahill, Susan M. Chang, Joseph F. Costello, Craig Horbinski, Raymond Y. Huang, Robert B. Jenkins, Keith L. Ligon, Ingo K. Mellinghoff, L. Burt Nabors, Michael Platten, David A. Reardon, Diana D. Shi, David Schiff, Wolfgang Wick, Hai Yan, Andreas von Deimling, Martin van den Bent, William G. Kaelin, Patrick Y. Wen

Summary: This article discusses the diagnosis and management of IDH-mutant gliomas, as well as new treatment methods and future research directions.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Stroke-associated infections in patients with and without cancer

Katharina Seystahl, Juliane Schweizer, Mira Katan, Sung Ju Weber, Alessia Hug, Miriam Wanner, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller

Summary: Cancer is not a risk factor for stroke-associated infections in stroke patients. The incidence, characteristics, and treatment of infections did not differ significantly between stroke patients with and without cancer. However, both cancer and stroke-associated infections were associated with in-hospital mortality.

NEURO-ONCOLOGY PRACTICE (2023)

添加到收藏夹

Article Oncology

Immunotherapy for brain metastases and primary brain tumors

Anna M. Di Giacomo, Maximilian J. Mair, Michele Ceccarelli, Andrea Anichini, Ramy Ibrahim, Michael Weller, Michael Lahn, Alexander M. M. Eggermont, Bernard Fox, Michele Maio

Summary: The conditions that promote immunotherapy responses in primary or secondary brain malignancies were discussed during the V Siena Immuno-Oncology (IO) Think Tank meeting in 2021. Important publications in 2021 and 2022 have reinforced the core elements of these discussions. While current immunotherapies have failed to benefit patients with primary brain tumors like glioblastoma, they have shown positive responses in brain metastases. The differences between these conditions seem to be influenced by intrinsic and extrinsic factors, such as driver mutations, the blood-brain barrier, and the immune suppressive microenvironment. Future therapeutic interventions may focus on rebalancing the immune cell population to enable better responses to current and future immunotherapies.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Association of antidepressant drug use with outcome of patients with glioblastoma

Corinna Seliger, Felix Boakye Oppong, Florence Lefranc, Olivier Chinot, Roger Stupp, Burt Nabors, Thierry Gorlia, Michael Weller, EORTC Brain Tumor Group

Summary: Depressive symptoms are common in glioblastoma patients, but they are often not treated with antidepressants. Limited evidence suggests that the use of antidepressants is not significantly associated with progression-free or overall survival in glioblastoma patients. However, using antidepressants at the start of maintenance cycle 4 is significantly associated with worse overall survival. Antidepressant use is not significantly associated with seizures, cognitive changes, or fatigue, except for an increase in fatigue during maintenance treatment. Confirmation and further study are needed to assess the impact of antidepressant use on the survival of glioblastoma patients. Prospective trials should evaluate the efficacy, side effects, and outcomes of antidepressant treatment in glioblastoma.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Differential roles of type I interferon signaling in tumor versus host cells in experimental glioma models

Evelina Blomberg, Manuela Silginer, Patrick Roth, Michael Weller

Summary: Despite various treatment approaches, the survival rate for glioblastoma patients remains low. This study implicates that constitutive type I interferon signaling in gliomas may promote tumor growth, but only in a microenvironment with a proficient type I interferon signaling in the host.

TRANSLATIONAL ONCOLOGY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

A risk model for prediction of diagnosis of cancer after ischemic stroke

Katharina Seystahl, Dorothee Gramatzki, Miriam Wanner, Sung Ju Weber, Alessia Hug, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller

Summary: The occurrence of cancer in stroke patients can be associated with elevated levels of white blood cells, platelets, and d-dimers. Additionally, the presence of ischemic lesions in multiple vascular territories is also linked to cancer diagnosis within one year after stroke.

SCIENTIFIC REPORTS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.